Definitive Contract 75N92020C00019
Award Date
8/28/20
Potential Completion Date
6/30/21
Potential Value
$5.3M
Federal Agency
National Heart Lung and Blood Institute
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lincoln, NE 68507, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) National Institutes of Health National Heart Lung and Blood Institute awarded a $5,253,450.00 firm fixed-price contract to Maxim Biomedical, Inc. to provide RADX TECH SARS-COV-2 antigen rapid tests. The contract has an estimated completion date of August 27, 2023 and was awarded on August 28, 2020. Maxim Biomedical is a small disadvantaged, woman-owned, Asian-Pacific American owned business that specializes in medical device manufacturing,...
Minute Molecular Diagnostics, Inc. was awarded a definitive, firm fixed price contract valued at seventeen million, five hundred ninety thousand dollars by the Department of Health and Human Services' National Institutes of Health National Heart, Lung and Blood Institute. The contract is for the RADX TECH PROJECT 2200 to develop a high-throughput, fast-turnaround, field-deployable COVID-19 molecular diagnostic system. Work will be performed in Evanston, Illinois with a period of performance...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded an $18.2 million firm fixed price definitive contract to Quanterix Corporation as part of the Rapid Acceleration of Diagnostics initiative. The RADx program aims to expedite the development, commercialization, and implementation of Covid-19 testing technologies to significantly increase domestic testing capacity. Quanterix will support this objective through the delivery of diagnostic solutions over a two-year...
Mammoth Biosciences Inc., doing business as Mammoth Diagnostics, has been awarded a $20.8 million firm fixed price definitive contract by the National Institutes of Health's National Heart, Lung, and Blood Institute to support the RADX Tech program. Under this contract, Mammoth Diagnostics will utilize its CRISPR-based Detectr platform to develop assays for the detection of SARS-CoV-2, the virus that causes COVID-19. The work will be performed in South San Francisco, California over an...
This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Detect Inc. for the Rapid Acceleration of Diagnostics (RADx) Tech II program. The contract is valued at $8,085,388.00 and has a firm fixed price pricing type. The contract is for the "Expanded Manufacturing and Commercialization of 'Detect' COVID-19 Test: Highly Scalable, Affordable, At-Home Rapid Test" project, with a completion date of October 13, 2022. This contract...
The Department of Health and Human Services National Institutes of Health National Institute of Biomedical Imaging and Bioengineering awarded a $20.7 million firm fixed price definitive contract to Associated Pathologists, LLC (doing business as Pathgroup) for the Rapid Acceleration of Diagnostics (RADX) ATP Program - Project #7338. The contract is being funded under the Coronavirus COVID-19 national interest action code and will support RADX's goal of accelerating the development,...
The National Institutes of Health awarded a $50.7 million firm fixed price modification to MicroGEM US Inc. under the RADX Tech Program. The modification extends an existing contract to maintain MicroGEM's production of 160,000 saliva-based, high-performing RT-PCR point-of-care cartridges and 1,000 portable devices per day for COVID-19 testing. The 25-minute tests and devices are non-invasive and portable. Funding comes from the Department of Health and Human Services National Institutes of...
The Broad Institute, Inc., doing business as the Broad Institute of MIT and Harvard, has been awarded a definitive contract valued at $25.7 million by the National Institutes of Health's National Heart, Lung and Blood Institute to scale the Broad Institute's reverse transcription polymerase chain reaction (RT-PCR) process to support testing of over 100,000 samples per day. This contract is part of the Rapid Acceleration of Diagnostics (RADx) Advanced Technology Platforms program, which aims to...
This is a $6,250,000.00 firm fixed-price definitive contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Meridian Bioscience Inc., a foreign-owned, for-profit manufacturer of in vitro diagnostic test kits and medical testing technologies. The contract is for the Rapid Acceleration of Diagnostics (RADx) Tech Project #6139, which involves the supply of Meridian Bioscience's RevogeneⓇ SARS-CoV-2 assay. This diagnostic test is being procured to support the...
Sonic Healthcare USA Inc. was awarded a firm fixed price definitive contract valued at $20,550,149.95 by the National Institutes of Health National Heart Lung and Blood Institute to rapidly expand existing framework for deploying large-scale COVID-19 RT-PCR testing platforms and distributing testing capacities under the Rapid Acceleration of Diagnostics program. The work will be performed in Austin, Texas over a one year period ending in August 2021. This contract was awarded non-competitively...